Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00312351 · ClinicalTrials.gov registry record · Phase 4
A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)
A Phase 4 study, sponsored by Eyetech Pharmaceuticals.
- Terminated
- Registry status
- Phase 4
- Development phase
- 262
- Enrollment target
NCT00312351 is a Phase 4 study that was terminated before completion, run by Eyetech Pharmaceuticals. The registered enrollment target is 262 participants.
The verdict
NCT00312351, a Phase 4 study, was terminated before completion, sponsored by Eyetech Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 262 participants
- Enrollment target
Study Summary
The purpose of this trial is to compare the ability of three different doses of pegaptanib sodium to safely and effectively minimize fluid leakage within the eye, thereby stabilizing or improving vision in patients with wet AMD. The study will also examine the effects of pegaptanib sodium on the cornea and sensory retina of patients with wet AMD.
Interventions
- DRUG Pegaptanib sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 262 participants |
| Start Date | 2006-04 |
| Est. Completion | 2006-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00312351
The ClinicalTrials.gov registry entry for NCT00312351 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 262 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eyetech Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pegaptanib sodium is the first listed.
NCT00312351 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00312351 about?
NCT00312351 is a clinical study titled "A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)". The purpose of this trial is to compare the ability of three different doses of pegaptanib sodium to safely and effectively minimize fluid leakage within the eye, thereby stabilizing or improving vision in patients with wet AMD. The study will also examine the effects of pegaptanib sodium on the cor...
What is the current status of trial NCT00312351?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 262 participants. The study started on 2006-04. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00312351?
The interventions under investigation include: Pegaptanib sodium (DRUG).
Who is sponsoring clinical trial NCT00312351?
This trial is sponsored by Eyetech Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.